[引用][C] Epidemiological aspects of Graves' disease

G Benker, D Reinwein, P Kotulla… - European Journal of …, 1986 - academic.oup.com
The remission rates of hyperthyroidism achieved by antithyroid drug treatment vary greatly.
One ex¬ munogenic hyperthyroidism. Page 1 values ranged from 36.7 (group 4) to 62.0 (group …

Goiter at Diagnosis Might Be Predicting Factor for Early Onset Intractable Graves' Disease

S Kim, GH Nam, N Lee, S Kim, MB Ahn… - Journal of the …, 2021 - ncbi.nlm.nih.gov
Introduction: The clinical course of Graves' disease (GD) treated with anti-thyroid drug (ATD)
treatment were reviewed with the aim of establishing criteria able to predict intractable GD …

Factors influencing the outcome of thyrostatic drug therapy in Graves' disease

B Winsa, PA Dahlberg, R Jansson… - European Journal of …, 1990 - academic.oup.com
In patients with Graves' disease, thyrostatic drug treatment may induce definitive remission
without the need of more aggressive measures such as surgery or radioiodine. Following …

Differences and similarities in the treatment of diffuse goiter in Europe and the United States

L Wartofsky, D Glinoer, B Solomon… - Experimental and …, 1991 - thieme-connect.com
In two separate studies, members of the American Thyroid Association (ATA), and the
European Thyroid Association (ETA) were surveyed by questionnaire on their management …

Endocrinology and Metabolism

PJ Mitchell, P Platt, C Wren, PJ Mitchell, P Platt… - Handbook of Hospital …, 1983 - Springer
ENDOCRINOLOGY AND METABOLISM Page 1 8 ENDOCRINOLOGY AND METABOLISM
Thyrotoxicosis COMMON CAUSES - Graves' disease (hyperplasia) - toxic nodular goitre …

Current trends in the management of Graves' disease

B SOLOMON, D Glinoer, R Lagasse… - The Journal of …, 1990 - academic.oup.com
Members of the American Thyroid Association were invited to participate in a survey of the
management of Graves' disease. One primary case and several variations were provided …

[引用][C] Enhanced suppression of 1,25(OH)2D3 levels in Graves' disease (GD) as compared to toxic nodular goiter (TNG) independent of T3 elevations: A …

H Czernobilsky, H Schmidt-Gayk… - European Journal of …, 1984 - academic.oup.com
Conclusion: Plasma and urinary Ca levels dropped and l, 25 (OH) 2D3 levels rose after
treatment in both GD and TNG, demonstrating a similar calcium homeostasis. A difference …

Goitre size and outcome of medical treatment of Graves' disease

P Laurberg, PEB Hansen, E Iversen… - European Journal of …, 1986 - academic.oup.com
One hundred and twenty-four patients with newly diagnosed hyperthyroidism received a
combined thionamid-thyroxine medical therapy for approximately 2 years. According to the …

[PDF][PDF] Graves' disease in men's subjects

D Diédhiou, IM Diallo, MA Ndour, D Sow… - J Hum …, 2018 - researchgate.net
Conclusion Graves' disease in male subject is characterized by delayed diagnosis, a larger
goiter, a high rate of lost sight and relapse. The follow-up needs to take into account the risk …

[HTML][HTML] A Clinical Debate: What Is the Therapeutic Choice for Recurrent Graves' Hyperthyroidism?

H Abdi, SR Zakavi, F Azizi - International journal of endocrinology …, 2020 - ncbi.nlm.nih.gov
Ms. EA is a 36-year-old woman who has been referred for the management of recurrent
hyperthyroidism. She was always healthy with no significant medical history until about 30 …